Given the previous concerns regarding PSA and possible overdiagnosis of indolent, low-grade prostate cancer, we stress the importance of demonstrating the robustness and generalizability of non-invasive biomarker tests such as MPS and MPS2. The gene discussed is KLK3; the disease is prostate carcinoma.